By Dr William Brooks

Conference Abstracts

Bateman R; Aschenbrenner A; Benzinger T; Clifford D; Cruchaga C; Fagan A; Farlow M; Goate A; Gordon B; Hassenstab J; Jack C; Koeppe R; McDade E; Mills S; Morris JC; Salloway S; Santacruz A; Snyder P; Wang G; Xiong C; Snider BJ; Mummery C; Surti G; Didier H; Wallon D; Berman S; Lah J; Jimenez-Velazquez IZ; Roberson E; Van Dyck C; Honig LS; Valle RS; Brooks WS; Gauthier S; Masters C; Galasko D; Brosch J; Hsiung R; Jayadev S; Formaglio M; Masellis M; Clarnette R; Pariente J; Dubois B; Pasquier F; Andersen S; Holdridge K; Mintun M; Sims J; Yaari R; Baudler M; Delmar P; Doody R; Fountouro P; Kerchner G, 2020, 'DIAN-TU Alzheimer's Disease Prevention Trial of Solanezumab and Gantenerumab: Amyloid, Tau and Neurodegeneration Outcomes', in ANNALS OF NEUROLOGY, WILEY, ELECTR NETWORK, Vol. 88, pp. S103 - S103, presented at 145th Annual Meeting American-Neurological-Association, ELECTR NETWORK, 04 October 2020 - 09 October 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000572509100139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Weickert T; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks W; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd A; Stanton C; O'Donnell M; Liu D; Galletly C; Weickert CS, 2019, 'Reduction in Peripheral C-Reactive Protein Levels With Canakinumab Administration is Related to Reduced Positive Symptom Severity in Patients With Schizophrenia and Inflammation', in BIOLOGICAL PSYCHIATRY, ELSEVIER SCIENCE INC, IL, Chicago, Vol. 85, pp. S44 - S45, presented at 74th Annual Meeting of the Society-of-Biological-Psychiatry (SOBP), IL, Chicago, 16 May 2019 - 18 May 2019, http://dx.doi.org/10.1016/j.biopsych.2019.03.121

Weickert T; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks W; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd A; Stanton C; O'Donnell M; Liu D; Galletly C; Weickert CS, 2019, 'REDUCTION IN PERIPHERAL C-REACTIVE PROTEIN LEVELS WITH CANAKINUMAB ADMINISTRATION IS RELATED TO REDUCED POSITIVE SYMPTOM SEVERITY IN PATIENTS WITH SCHIZOPHRENIA AND INFLAMMATION', in SCHIZOPHRENIA BULLETIN, OXFORD UNIV PRESS, FL, Orlando, Vol. 45, pp. S318 - S318, presented at Congress of the Schizophrenia-International-Research-Society (SRIS), FL, Orlando, 10 April 2019 - 14 April 2019, http://dx.doi.org/10.1093/schbul/sbz020.578

Dobson-Stone C; Shaw A; Brooks W; Loy C; Schofield P; Mather K; Kochan N; Sachdev P; Halliday G; Piguet O; Hodges J; Kwok J; Ittner L; Fath T; Housley G, 2015, 'Utility and challenges of whole-exome sequencing in the hunt for neurodegeneration genes [Abstract MTU02-05]', in Journal of Neurochemistry, Wiley: 12 months, Cairns, Australia, Vol. 134, pp. 111 - 111, presented at 25th Biennial Meeting of the International Society for Neurochemistry Jointly with the 13th Meeting of the Asian Pacific Society for Neurochemistry in Conjunction with the 35th Meeting of the Australasian Neuroscience Society, Cairns, Australia, 23 August 2015 - 27 August 2015, http://dx.doi.org/10.1111/jnc.13188

Back to profile page